MedDataX Logo

A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province

NCT ID: NCT05130424

Last Updated: 2021-11-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

498 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-29

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To observe and evaluate the safety and effectiveness of herombopag in the treatment of thrombocytopenia-related diseases in Henan Province

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed as a real-world study on the treatment of thrombocytopenia-related diseases with Herombopag, to observe and analyze the safety and efficacy of Herombopag for thrombocytopenia-related diseases in the real world.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma;Blood

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Herombopag

Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Thrombocytopenia related diseases;
2. Volunteer to join this study and sign an informed consent form;
3. Clinical evaluation can benefit from Herombopag.

Exclusion Criteria

1. Those who have been confirmed to be allergic to Herombopag and/or its excipients;
2. Pregnant or breastfeeding women;
3. Except for patients with contraindications to Herombopag;
4. Doctors evaluate patients who are not suitable for inclusion.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SuxiaLuo

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

SuxiaLuo

chief physician

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Henan Cancer Hospital

Zhengzhou, Henan, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

suxia luo

Role: CONTACT

Phone: 18638553211

Email: [email protected]

wenying deng

Role: CONTACT

Phone: 15837168169

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Suxia Luo, Doctor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HNHQRWS

Identifier Type: -

Identifier Source: org_study_id